DIAGNOSTIC METHODS
First Claim
1. A method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has an altered susceptibility to statin-induced myopathy.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.
-
Citations
25 Claims
- 1. A method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has an altered susceptibility to statin-induced myopathy.
-
2. A method of reducing the risk of myopathy in an individual during treatment with a statin, comprising
i) detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual; -
ii) classifying the individual according to their susceptibility to statin-induced myopathy, by reference to the presence or absence of the one or more polymorphisms detected in step i); and iii) determining a suitable dosage for statin treatment by reference to the susceptibility of the individual to statin-induced myopathy determined in step ii). - View Dependent Claims (17, 18, 19)
-
-
6. A method of determining a suitable dosage for an individual in need of treatment with a statin, comprising
i) determining whether the genotype of the individual is heterozygous or homozygous for one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual; - and
ii) determining a suitable dosage for statin treatment by reference to the genotype of the one or more polymorphisms, whereby a standard dose of a statin is suitable for an individual with a heterozygous or homozygous high-risk genotype and a higher dose is suitable for an individual with a homozygous low-risk genotype. - View Dependent Claims (8, 9, 10, 11, 12, 13)
- and
-
7. A method of treating an individual in need of treatment with a statin, comprising
i) determining whether the genotype of the individual is heterozygous or homozygous for one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual; -
ii) classifying the individual according to their genotype at the one or more polymorphisms as determined in step i); and iii) administering a dose of a statin, whereby a standard dose of a statin is suitable for an individual with a heterozygous or homozygous high-risk genotype and a higher dose is suitable for an individual with a homozygous low-risk genotype. - View Dependent Claims (20, 21, 22, 23, 24, 25)
-
- 14. An in-vitro diagnostic kit for screening for susceptibility of an individual to statin-induced myopathy, comprising one or more reagents for detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual.
Specification